Association of drug exposure with clinical response and toxicities in metastatic renal cell carcinoma patients (mRCC) receiving an alternative dosing (AD) regimen of sunitinib. Downregulation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results